Enabling better management of patients: discrete event simulation combined with the STAR approach by Demir, Eren & Southern, David
Research Archive
Citation for published version:
Eren Demir, and David Southern, ‘Enabling better management 
of patients: discrete event simulation combined with the STAR 
approach’, Journal of the Operational Research Society, Vol. 68 
(5): 577-590, December 2017.
DOI:
https://doi.org/10.1057/s41274-016-0029-y
Document Version:
This is the Accepted Manuscript version. 
The version in the University of Hertfordshire Research Archive 
may differ from the final published version.  
Copyright and Reuse: 
This manuscript version is made available under the terms of 
the Creative Commons Attribution licence CC BY 4.0 
(http://creativecommons.org/licenses/by/4.0/), which permits 
unrestricted re-use, distribution, and reproduction in any 
medium, provided the original work is properly cited.  
Enquiries
If you believe this document infringes copyright, please contact Research & 
Scholarly Communications at rsc@herts.ac.uk
  1 
Enabling better management of patients: discrete event simulation 
combined with the STAR approach 
 
 
Abstract 
Squeezed budgets and funding cuts are expected to become a feature of the healthcare 
landscape in the future, forcing decision makers such as service managers, clinicians 
and commissioners to find effective ways of allocating scarce resources. This paper 
discusses the development of a decision support toolkit (DST) that facilitates the 
improvement of services by identifying cost savings and efficiencies within the 
pathway of care. With the help of National Health Service and commercial experts, 
we developed a discrete event simulation model for Deep Vein Thrombosis (DVT) 
patients and adapted the socio technical allocation of resources (STAR) approach to 
answer crucial questions like: what sort of interventions should we spend our money 
on? Where will we get the most value for our investment? How will we explain the 
choices we have made? The DST enables users to model their own services by 
working with the DST interface allowing users to specify local DVT services.  They 
can input local estimates, or data of service demands and capacities, thus creating a 
baseline discrete event simulation model. The user can then compare the baseline with 
potential changes in the patient pathway in the safety of a virtual environment. By 
making such changes key decision makers can easily understand the impact on 
activity, cost, staffing levels, skill-mix, utilisation of resources and, more importantly, 
it allows them to find the interventions that have the highest benefit to patients and 
provide best value for money.  
 
Keywords: Discrete event simulation, STAR, decision support toolkit, deep vein 
thrombosis, patient flow modelling. 
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1 Introduction 
 
The treatments of chronic diseases are complex and resource intensive, requiring 
multi-disciplinary teams including radiologists, specialist nurses, consultants and 
pharmacists.  Combining this with a continuously increasing population and increased 
life expectancy (ONS, 2013), it is clear that healthcare systems around the world will 
find the management of such patients more and more challenging. In England in 
particular, the National Health Service (NHS) is faced with additional pressures 
stemming from ever increasing resource and capacity constraints, e.g. reduction in 
budgets, fewer doctors and nurses, reduced number of hospital beds.   
 
To help guide key decision makers easy to use tools are needed to find ways of 
increasing efficiency/productivity and improving quality of services. The tool should 
respond to the concerns of end users and enable them to achieve a better 
understanding of the system structure and operations, and how these influence key 
performance metrics, such as activity results (e.g. the number of patients treated per 
year), resource utilisation levels (e.g. radiologist, clinician, nurses and beds), clinical 
and cost outcomes. In this context, the tool should accommodate the playing-out of a 
range of policies and scenarios relevant to decision makers and allow testing of the 
possible impact of these scenarios on the care system performance indicators. For 
example, the tool could determine the likely resource utilisation impact of a new 
policy whereby more patients are treated in the community as opposed to hospital. 
This could then enable the design of more pro-active and better-informed policies and 
help towards their integration into the commissioning process. 
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The tool should also tackle some of the commissioning challenges. Often 
commissioners are confronted with the following questions: what sort of interventions 
should we spend our money on? Where will we get the most value for our 
investment? How will we explain the choices we have made? These choices are 
difficult and they matter. More importantly is there an objective way of answering 
these questions?  
 
To tackle these issues (and more) we describe a DST that was developed with the aim 
of assisting those responsible with the management, commissioning and treatment of 
Deep Vein Thrombosis (DVT) in the UK. DVT is a condition in which a blood clot 
(thrombus) forms in a vein.  In 2005, it was estimated that 25,000 people in the UK 
die from preventable hospital-acquired venous thromboembolism per annum (NICE, 
2014a).  Every year, one in a thousand people in the UK is affected by this disease 
(NICE, 2014a). The risk of developing DVT also depends on a series of secondary 
factors such as immobility, age, existing cancer symptoms, pregnancy, obesity and 
sex (NICE, 2014a).  Other concomitant conditions may also have an impact on a 
patient developing a DVT.  The diagnosis has profound implications for the 
individual and their family, as well as major cost implications for hospitals and 
community services.   
 
Having created a baseline discrete event simulation model and established its face 
validity, the DST captures the complexity of DVT services at a sufficient level and 
operates within a user friendly environment, that is, an interface was built to allow 
users to specify their own local DVT service and input their own estimates or data of 
service demands and capacities. The main strength of this decision support tool is the 
adoption of a team approach to studying the system, involving DVT specialist nurses 
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across the country, ensuring that a variety of views and suggestions are taken, as well 
as systems modelling and simulations.  
 
The DST further introduces the Socio-Technical Allocation of Resources (STAR) 
(Airoldi et al., 2014) which is an approach to assess the cost-effectiveness of all 
interventions considered for resource allocation by adding health economics concepts 
to the discrete event simulation model to integrate aspects such as scale, costs and 
benefits more clearly. In the case of DVT, the variety of treatment options (either in 
the community or hospital) can be seen as interventions. Service providers and 
commissioners are particularly interested in finding the interventions that has the 
highest benefit to patients and provide best value for money.  
 
Most analyses underpinning recommendations as to which interventions should be 
provided are difficult to understand, for example, cost effective analysis (CEA) 
carried out by the National Institute for Health and Clinical Excellence (NICE) for 
each drug. CEA is not appropriate for local decisions on resource allocation over the 
mix of services that ought to be provided, which entail making trade-offs to allocate a 
fixed budget every year within national policies (Airoldi et al., 2014). We visually 
illustrate the relative cost-effectiveness of interventions and interpret the results in a 
simple and concise manner, so that it could easily be understood by a commissioner, 
service provider, clinician and nurses. This is crucial to ensure speedy and effective 
decision making for change.  
 
The current study therefore has three objectives.  
 
1) Explore the impact of a range of changes to the Deep Vein Thrombosis 
disease pathway using discrete event simulation (DES) and to explore the 
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utility of this approach in this setting. Simulating patient pathways brings 
together an individual patient’s entire journey for their medical condition (i.e. 
longitudinal cycle of care), capturing variation as they flow through the care 
system and incorporating a large number of different patient attributes such as 
length of stay, age, gender and disease stage. It allows for the running of the 
model over extended time horizons. Patients move through the model and they 
can experience events at any point in time, such as a series of diagnosis, 
treatment (including pharmaceuticals), follow-ups, disease progression, etc. 
2) DES studies usually just examine the trade-offs between resources 
(utilisations) and service as measured by the availability of care, often waiting 
times. We adapt the STAR approach within DES to help local decision makers 
decide which of the interventions for DVT patients are likely to generate the 
greatest health benefit, with the highest value for money. Therefore, this study 
aims to consider wider measures of quality of health care. 
3) Develop a user friendly decision support toolkit (a further development on the 
DES model) to enable users to interact with the model by allowing them to 
make necessary changes to the input parameters, so that the model is service 
specific with a customized set of results, focusing on activity, costing, value 
for money and resource utilization. These indicators are known to be valuable 
for key decision makers in the process of commissioning and re-designing 
services. This toolkit would provide the user with the ability to compare and 
contrast results from one scenario with another scenario with the results 
dependent on the variables specified by the user.  
 
For illustration purposes we experiment to assess the possible impact of shifting more 
DVT patients from hospital care to community care services using the new treatment 
known as novel oral anticoagulant (NOAC) which is a new class of anticoagulant 
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drug, as opposed to standard of care (i.e. Warfarin). In addition to many outputs 
comparing the experiments based on key performance metrics, the STAR approach is 
implemented to examine which of the four possible interventions provide best value 
for money and benefit the patients most. The interventions are, 1) continue with the 
usual hospital treatment with Warfarin, 2) treat patients with NOAC in hospital, 3) 
treat with Warfarin in the community, and 4) treat with NOAC in the community. The 
policy rationale is that reducing the number of visits to hospital without affecting the 
quality of treatment (more importantly the outcome on patients), is strongly supported 
by the Department of Health in England, and therefore the DST should assist decision 
makers in changing the pathway for effective use of resources (i.e. the interventions 
that provide best value for money and benefits the patients most). 
 
The next section provides an up-to-date review of the literature on healthcare 
simulation and application of DES for health economic modelling purposes. We then 
illustrate a qualitative map portraying the inner workings of the DVT pathway, model 
building assumptions, the input parameters, and describe the STAR approach in 
Section 3. All results with model outputs and scenarios are discussed in Section 4. 
Finally, in section 5 we discuss the limitations, usefulness and implications in 
practice. 
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2 Healthcare Simulation 
One might ask a simple question “why is simulation needed?” Why can’t a simple 
calculation estimate the number of visits to hospital and/or costs associated with each 
intervention? There are marked differences between a simulation and cohort models 
(e.g. Excel based calculations). Cohort patient models estimate the outcome for a 
group of patients without explicitly considering the outcomes for each individual.  
They treat patients as sets of homogenous groups and view them in terms of “states” - 
healthy, ill or dead.  They are difficult to adapt and hard to communicate, whereas a 
simulation captures all uncertainties (through distributional assumptions) such as 
variation in patient arrivals, diagnosis process, treatment and follow-ups, and thus the 
opportunity of capturing reality (to a certain extent). More importantly, the model 
enables us to incorporate individual event’s resource needs (e.g. consultant, nurse, 
consultation room, medication, etc.), enabling us to quantify the utilization of such 
resources. 
 
Discrete Event Simulation (DES), System Dynamics (SD) and Agent Based 
Simulation (ABS) are the three popular simulation methodologies. DES has the 
ability to model individual patients and their unique trajectories as they flow through 
the care system and to incorporate a large number of different patient attributes such 
as age, gender and disease stage. It allows for the running of the model over extended 
time horizons. Patients move through the model and they can experience events at any 
discrete point in time.  
 
SD divides populations into large homogenous groups, where each group of patients 
in the same clinical/care state is represented by the same variable state. The modelling 
of patients flows then aims to track the transition of these groups of patients between 
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the variable states and not the flow of each individual patient within the population 
(Brailsford, 2004).  
 
ABS views the world differently to DES and SD. An Agent is an autonomous entity 
which has the ability to make decisions and therefore the focus in ABS, is to model 
how a decision is made. Individual behaviour of an agent is modelled and then 
multiple entities are sent to the environment in order for them to interact with each 
other and with the environment (Macal and North, 2010). 
 
Out of the three simulation approaches (DES, SD and ABS), we have chosen to 
develop our model using DES as it allows for the running of the model over extended 
time horizons and enables tracking of individual patients footsteps in service and has 
the ability to incorporate capacity and resource constraints, hence capturing reality 
within a software environment (Simul8). Furthermore, it is an approach well 
understood and accepted by the NHS community, including clinicians, nurses, service 
managers and senior executives.    
 
2.1 DES for health economic modelling purposes  
Many DES models have been developed to support the planning of healthcare 
services including the operation of accident and emergency departments (Codrington‐
Virtue et al. 2005), English cervical cancer screening programme (Pilgrim and 
Chilcott, 2008), improvement measures in outpatient orthopaedics clinic (Rohleder et 
al. 2011), management of patients with Parkinson’s disease (Demir et al. 2015), and 
many more. The literature in DES applied to healthcare services is vast. See Gunal 
and Pidd (Gunal and Pidd, 2010) for a comprehensive review of the literature on DES 
for performance modelling in hospitals. Katsaliaki and Mustafee (Katsaliaki and 
Mustafee, 2011) also present simulation applications in healthcare.   
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Within the last few years DES models have also been applied to fields such as cost-
effectiveness analysis (or health economic modelling). Brennan et al (2006) suggests 
a taxonomy of model structures for economic evaluation of health technologies and, 
in doing so, identifies the role and importance of DES in health economics.   
 
Pilgrim et al. (2009) used DES to develop the complete colorectal cancer patient 
pathway to examine the potential cost-effectiveness of different options for change 
across the entire colorectal cancer pathway. The benefits of each option were 
measured in terms of incremental life years and quality-adjusted years (QALYs) 
gained. The former represents the additional expected number of years of life gained 
by an individual patient as a result of the new option, as compared against the current 
service. The latter outcome is a generic health utility measure, accounting for both 
duration and quality of life.  
 
Similar to the study by Pilgrim et al. (2009), Hideki and Barendregt (2011) developed 
a DES model that followed Australian population with osteoarthritis over their 
lifetimes. Intervention effects (i.e. total replacement of hips and knees) were modelled 
by means of disability-adjusted life-years (DALYs) averted, and one of their key 
findings was that both hip and knee replacements are cost-effective interventions to 
improve the quality of life of people with osteoarthritis. 
 
Stahl et al. (2004) examined the effect of radically redesigning the delivery of 
anaesthesia care and determined the cost effectiveness of changes to balance 
efficiency and surgical safety of patients undergoing laparoscopic cholecystectomy.  
The impact of continuing with the current practice where an anaesthesiologist remains 
at all times until surgery is complete (including recovery) was compared against 
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several other staffing strategies, for example, physicians and nurses for anaesthesia 
coverage (the proposed new practice).  DES was used to compare these two strategies 
and according to the cost-effectiveness analysis, the proposed new practice is more 
effective and less costly.  
 
NICE recently published a comprehensive report (NICE, 2014b) on cost effectiveness 
modelling using patient level simulation. The report exhaustively compares existing 
modelling techniques against DES. Typically, existing methods are decision trees and 
Markov Chain Monte Carlo simulation applied for cost effectiveness analysis 
purposes, e.g., QALYs and incremental cost effectiveness ratio (ICER). Given the 
exhaustive nature of the report it is clear that no matter what modelling methodology 
is utilised the health economic modelling is always the same (QALYs and ICER) 
combined with sensitivity analysis.  Note that NICE plays a very important role in 
England in the use of health technologies within the NHS, such as the use of new and 
existing medicines, treatments and procedures.   
 
Other DES models were also developed for similar purposes. Igarashi et al. (2016) 
compared the health and economic consequences in Japan of using pharmacotherapy 
to support smoking cessation with unassisted attempts and the current mix of 
strategies used. According to their findings, increased utilisation of smoking cessation 
pharmacotherapy to support quit attempts is predicted to provide improvements in 
health outcomes over a lifetime with no additional costs. A similar study was also 
conducted by Getsios et al. (2013) and Mayorga et al (2014) estimating the health and 
economic outcomes associated with smoking cessation interventions. Comas et al. 
(2014) assessed the cost-effectiveness of switching from one method of breast cancer 
screening to another (i.e. screen-film mammography to digital mammography). An 
interesting study was conducted by Verjan et al (2013), where the economic impact of 
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providing healthcare at home was compared against traditional hospitalisation using 
modelling with Petri nets and discrete event simulation.  A key finding was that 
healthcare at home can be used to control and improve patients flow on hospitals. 
 
Our approach of combining DES with the STAR approach is unique in its response to 
the concerns and needs of key decision makers, where the adaptation of the STAR 
approach could easily help commissioners/clinicians determine the interventions that 
have the greatest health benefit and that provide best value for money. In all of the 
above instances, either QALYs and/or ICER were utilised for cost effectiveness 
analysis. It is clear from the literature review and authors’ domain knowledge, to date 
no model has been developed and implemented tackling all the above specified 
challenges within a single DST framework. 
 
3 Material and methods  
3.1 Additional setting description  
The first stage of the pathway mapping was to research the current practices within 
the industry, which occur for the particular disease being evaluated.  This included 
utilising publications from the industry, such as the National Institute of Clinical 
Excellence and other sources of information, which are recognised within the 
industry.  This allowed a baseline plan of the treatment events and a range of ‘what-if’ 
scenarios for a particular patient within the patient pathway.   
 
The second phase of the pathway mapping consisted of structured interviews with 
DVT nurses across a number of clinics between March and July 2013. The interviews 
were conducted ‘on line’ using technology to allow the interviewer to share a working 
diagrammatic representation of the pathway. The interviewer discussed each stage of 
the pathway with the interviewee taking account of the interviewee’s opinion and 
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adjusting the pathway in ‘real time’ as comments were made. Once the interviewee 
was satisfied with the structure of the pathway, the interview was closed. The 
interviews were recorded so that the interviewer could review comments after the 
event to ensure that all salient points had been captured.  In total six experts were 
interviewed iteratively.  The objective was to explore the DVT pathway in order to 
establish what, in the experts’ opinion, important areas were for development.  They 
viewed the number of options, which need to be static or variable for the simulation 
model to represent the possible scenarios which could be run by a clinic around the 
country.   
 
According to the interviews the typical care system in place in England, and 
elsewhere for diagnosing, treating and looking after patients with DVT, comprises a 
complex set of services offered in and out of hospital. Examples of care services 
offered in hospital include emergency care, outpatient appointments with specialists 
such as specialist nurses, access to advanced diagnostic procedures such as ultrasound 
and blood tests. In addition, each individual patient’s treatment option through the 
three main options of DVT influences to a large extent the type, location and intensity 
of care services in each individual’s care package. 
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Figure 1 Conceptualised pathway for DVT patients. 
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Figure 1 shows diagrammatically the inner workings of the DVT pathway. Arrivals 
are split into two: new patients and recurrent (those experiencing a recurrence of the 
disease) where 19% of arrivals are recurrent (Martinez, Rietbrock , Bamber , & 
Cohen, 2011).  The annual incidence rate of DVT is 104.6 patients per 100,000 
population, which is a parameter used as part of demand for DVT services (Martinez, 
Rietbrock , Bamber , & Cohen, 2011).  A patient can be presented to the service via 
their general practitioner (which is the majority of cases), accident and emergency, 
outpatient services or a community nurse. The diagnosis is made up of four stages: 
history and examination, Wells score, D-dimer test and an ultra sound. Wells score is 
a clinical prediction rule used to estimate the pre-test probability. This suggests 
whether a patient is at low, moderate or high risk of having suffered a DVT, which 
may guide subsequent investigation and management. Depending on who is 
delivering the service, the Wells score test can be carried out either by a GP or a 
clinician at an anticoagulation service.  
 
The Wells score on its own is not enough to confirm DVT, hence a D-dimer test is 
carried out (blood test), which detects pieces of blood clot that have been broken 
down and are loose in the bloodstream. The larger the number of fragments found, the 
more likely that the patient has a blood clot. However, the D-dimer test is not always 
reliable and therefore an additional test, an ultrasound scan, needs to be performed to 
confirm DVT.  The D-dimer test and ultrasound scan results can be categorized as 
positive or negative, whereas the Wells score is ranged from 0 to 9. A patient scoring 
greater than 2 is at a high risk of having suffered a DVT.  Wells et al. (2003) found 
that 46% of patients have a 'Wells Score' of greater than 2, whereas 30% of D-dimer 
(Wells, et al., 2003), 24% of ultrasound and  1% of repeat ultrasound tests are found 
to be positive, respectively (Goodacre, et al., 2006). 
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For a patient to be deemed to have a DVT, physicians rely on the combination of test 
results. Individual diagnostic outcomes expressed in probabilities (see Table 1) are 
multiplied to calculate the final outcome of diagnosis, that is, whether the patient is 
diagnosed for DVT (hence treatment) or not diagnosed (no treatment). For instance, if 
a patient has a positive Wells score (i.e. greater than 2), a negative D-dimer test result 
and a positive ultrasound result then treatment commences (7.728% of all cases - see 
Outcome 2 from Table 2). Note that there are many combinations and the percentages 
are calculated using the values shown in Table 2. For example, Outcome 1 is 
estimated to be 0.03312 (0.46*0.30*0.24).  
Diagnostic tests Probability of a positive 
diagnostic outcome (+) 
Probability of a negative 
diagnostic outcome (-) 
Wells Score 0.46 0.54 
D Dimer 0.30 0.70 
Ultrasound 0.24 0.76 
Repeat Ultrasound 0.01 0.99 
Table 1: Individual diagnostic outcomes expressed in probabilities. 
 Wells 
Score 
D-dimer 
test 
Ultrasound Probability Final Outcome 
Outcome 1 + (0.46) + (0.30) + (0.24) 0.03312 Treatment 
Outcome 2 + (0.46) - (0.70) + (0.24) 0.07728 Treatment 
Outcome 3 - (0.54) - (0.70) + (0.24) 0.09072 Treatment 
Outcome 4 - (0.54) + (0.30) + (0.24) 0.03888 Treatment 
Outcome 5 + (0.46) + (0.30) - (0.76) 0.10488 Repeat ultrasound 
Outcome 6 - (0.54) - (0.70) - (0.76) 0.28728 No treatment 
Outcome 7 + (0.46) - (0.70) - (0.76) 0.24472 Repeat ultrasound 
Outcome 8 - (0.54) + (0.30) - (0.76) 0.12312 Repeat ultrasound 
Total NA NA NA 1 NA 
Table 2: Combination of diagnostic tests and outcomes. + and – refers to positive and 
negative diagnostic outcome, respectively.  
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As the outcome of each diagnostic test is independent from each other, we assumed 
independence and thus multiplied to calculate the probability of the final outcome of 
diagnosis.  
 
According to the above calculations, around 29% of patients are discharged back to 
primary care (Outcome 6), i.e., no trace of DVT; 24% are diagnosed of DVT after an 
initial ultrasound test (P(Outcome 1) + P(Outcome 2) + P(Outcome 3) + P(Outcome4 
= 0.24)). The remaining 47% (Outcome 5+Outcome 7+ Outcome 11) have a repeat 
ultrasound. After similar calculations as above, we found that approximately 0.5% of 
repeated ultrasound patients are diagnosed with DVT and the remaining 99.5% are 
discharged back to primary care (no DVT).  
 
So far we have described the diagnosis aspect of the DVT care pathway. When a 
patient is diagnosed treatment commences within 1-4 weeks of diagnosis. The 
treatment arm distinguishes cancer from non-cancer patients.  Approximately 87.8% 
of DVT patients are non-cancer (Martinez, Rietbrock , Bamber , & Cohen, 2011). 
These patients are further categorised into groups: recurrent (recurrence of DVT, i.e. 
19% of all admissions are recurrent), 44.8% are provoked and 36.2% are unprovoked 
(Martinez, Rietbrock , Bamber , & Cohen, 2011). Provoked and unprovoked DVT 
types are not distinguished for cancer patients. Provoked DVTs can be linked to a 
discernible event such as surgery or plane travel, whereas unprovoked DVTs have no 
obvious causes. Patients could either be on standard of care or new treatment 
(NOAC). In standard of care all patients are initially treated with Low Weight 
Molecular Heparin (LMWH) in the first eight days followed by Warfarin in 
subsequent weeks and months.  
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Typically, 22%, 63% and 15% of provoked patients on Warfarin visit anticoagulation 
clinics (also known as INR clinics) on an average of 9, 14 and 24 times over 3, 6 and 
12 months, respectively (Winter, Keeling , Sharpen, Cohen, & Vallance, 2005) (Rose, 
James, Chapman, & Marshall, 2011). In the case of Unprovoked patients on Warfarin, 
6%, 63% and 31% visit INR clinics on average of 9, 14 and 24 times over 3, 6 and 12 
months, respectively. Similarly for recurrent patients, 3%, 42% and 55% visit 9, 14 
and 24 times over 3, 6 and 12 months, respectively.  
 
INR clinics have long been considered resource intensive due to the strict monitoring 
of the side effects of Warfarin, which in extreme cases can be life threatening. 
Conversely the under treatment of patients can lead to side effects. Newer treatments 
have far less severe side effects, thus enabling the rationalisation of the patient 
pathway. In the new treatment pathway (NOAC), patients have an initial visit (first 
attendance with the consultant) and a follow-up visit for routine review (in total 2 
outpatient attendances). Patients on standard of care are required to attend a clinic 
(under the control of a nurse) for treatment (9, 14 or 24 times over 3, 6 and 12 
months, respectively). Significant savings in time and other resources can be expected 
from the new treatment as a result of dramatic reductions in the number of visits to 
INR clinics. 
 
3.2 Model building including assumptions  
As is the case in modelling studies, some aspects of the real life service were not 
included in the model (if they were not relevant to the objectives of the study) and 
others were modified for simplification purposes.  These were discussed and agreed 
with the nurses and specialists who were consulted during the model building process. 
The model building (or conceptualisation) was mostly related to the telephone 
interviews held with six DVT specialist nurses. Other staff specialties (e.g. 
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administrative clerks, other specialists that were not included) and infrastructure 
elements (e.g. consultation rooms, mode of transportation used for community visits) 
that could be seen as capacity constraints, were not included in the model as these 
were not seen as critical by the stakeholders. There are no cancellations (either patient 
or service initiated) of outpatient consultations or community based visits. The 
presence of co-morbidities and other factors, such as socio-economic status or living 
arrangements, that may complicate the provision of care for a particular patient, were 
not included in the model. However, cancer patients diagnosed for DVT are regarded 
as a major complication, and thus the care pathway explicitly distinguishes these two 
groups, i.e., cancer and non-cancer patients have a unique flow within the model.  
Other complications such as presence of co-morbidities and other factors were not 
included, as recommended by nurses and specialists. 
 
3.3 Input parameters  
Model inputs included staffing levels, staff salary, staff availability, treatment 
pathways (hospital and the community), arrivals, discharges, percentage of patients 
falling into each category, costing of each service, existing and new patient arrivals 
and treatment option visit parameters (see the Table in Appendix for details). The vast 
majority of input parameters are pre-determined through in-depth review of the 
literature and, on a small number of occasions, nurses provided their expert opinion. 
Note that all input parameters are pre-populated and can be changed by the service 
provider (or purchaser) if the users deem this to be necessary to fit their geographical 
area.   
 
The input parameters cover a range of areas for the DVT simulation model 
comprising demand, diagnosis, treatment, costing, and salary attributes.  The demand 
for the service takes in to consideration the population and the annual increase in the 
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patient numbers each year.  The population is 104.6 patients per 100,000 in the 
general population (Martinez et al, 2011) and is collaborated by the Office of National 
Statistics (ONS).   
 
The treatment options for the service take into consideration the type of treatment 
provided to the patient, the length of treatment, the initial and follow up visits 
required dependent on patient type (e.g. provoked, unprovoked or recurrent).  Further 
attributes include how much time is taken for the visits to occur, as well as the 
responsibility for each type of staff connected with such a visit.  Each of these 
attributes are variable and can be determined by the user. The attributes are obtained 
through extensive research of the pathway and thorough detailed analysis of the 
treatment options which can be provided to a DVT patient.    
 
The costing option within the simulation model comprises the costs of initial and 
follow up visits within a haematology clinic, which are determined by the National 
Payment by Result Tariff (2013/2014). However, they can be overridden by the user 
(Payment by Result, 2013). An initial visit costs around £247.00 and a follow-up visit 
is £113.00.  The cost for the community treatment options are variable and can be 
determined locally, as this is an area where there can be variation dependent on the 
geographical region.  The drug costs are determined by the Monthly Index of Medical 
Specialities (MIMS).  Other costs which contribute to this area of the simulation 
model are the salaries of the staff involved, namely, haematologists, specialist nurses 
and radiologists (PSSRU, 2013).  Users can easily specify the number of available 
resources within their DVT services to analyse the effects of increasing/decreasing 
resources (see the Table in Appendix for an exhaustive list of the input parameters).   
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3.4 Socio Technical Allocation of Resources (STAR) 
The current healthcare landscape demands that those who plan or commission 
services at local, regional or national level provide high quality health and social 
services that offer good value for money. There is also a requirement to involve 
patients and the public in decisions about service planning. STAR helps those who 
plan or commission services to work with their stakeholders to allocate resources to 
benefit patients in their community.  In our context, the objective is to allocate scarce 
resources for the treatment of DVT.  The STAR methodology (Airoldi et al. 2014) is 
slightly modified to fit our purpose and is made up of the following components: 
 Costs(𝑐𝑗): the total cost of the entire pathway for patients in intervention j 
including individual patient’s footsteps in each service (e.g. diagnosis, 
treatment, drug acquisition costs and follow-ups), use of equipment and staff 
costing (hourly rates). 
 Population health benefit (𝑁𝑗 × 𝐵𝑗): the product of the number of patients who 
benefit from the intervention (𝑁𝑗) and the potential benefit (𝐵𝑗) in quality (and 
length) of life, assuming successful implementation, to the typical beneficiary, 
compared with current care. Health benefits are generally measured in quality-
adjusted life-years (QALYs). Due to time constraints and exploratory nature 
of this approach, Airoldi and colleagues (Airoldi et al. 2014) used direct rating 
with a visual analog scale technique on the basis of the evidence brought by 
clinical experts. During the nurse interviews DVT specialist nurses identified 
the intervention providing the greatest individual benefit, which was assigned 
a score of 100. They then scored the remaining three interventions relative to 
this benchmark score of 100. The interventions are, 1) continue with the usual 
hospital treatment with Warfarin, 2) use more NOAC in hospital, 3) treat 
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patients with Warfarin in the community, and 4) treat with NOAC in the 
community. 
 Feasibility (𝑝𝑗): Probability of success of achieving the assessed benefits.  
 Expected benefit 𝐸(𝑣𝑗): The model underpinning the evaluation is to Max 
∑ 𝐸(𝑣𝑗)𝑗 , which is the expected benefit from intervention j calculated as 
𝐸(𝑣𝑗) =  𝑝𝑗(𝑁𝑗 × 𝐵𝑗).  
 Value for money (VfM): 𝑉𝑓𝑀𝑗 = ( 
𝐸(𝑣𝑗)
𝑐𝑗
) × 1000 
 
The cost (𝑐𝑗) and the expected benefit 𝐸(𝑣𝑗) are presented using a right angle triangle 
known as value for money triangle. The horizontal side of the triangle represents the 
cost  (𝑐𝑗) associated with the intervention and the vertical side represents the expected 
benefit score 𝐸(𝑣𝑗) . The slope of the hypotenuse of the triangle represents cost-
effectiveness. The steeper the slope, the greater the ratio of health benefits to costs. 
The triangles are used to generate a priority list (graphically illustrated for ease of 
understanding) in which interventions are ranked according to value for money. 
 
4 Illustrative Results 
4.1 Simulation Parameters 
For illustration purposes of the model and the tool, we chose to evaluate the likely 
effect and size of some changes that seek to increase the use of new treatment 
(NOAC), in line with current policy guidance for DVT patients. The model was 
populated with a population of 250,000 (a typical size of a clinical commissioning 
group in England) at the beginning of year 1. The simulation was run for five years to 
capture the individual trajectories in the cohort over this period and to estimate the 
  22 
likely impact of changes in performance indicators related to activity, costs, and 
utilisation of resources (e.g. nurses, consultants and haematologists).  
 
The number of patients requiring treatment, which determines the level of demand on 
care services, is not constant over time but has an upward trend. The model captures 
this aspect through the year-to-year percentage increase in the number of patients in 
the service. The data for the yearly increase in arrivals is user specified and as such is 
determined by the values the user has entered (in this context a 1% increase is 
projected).  
 
In the interviews we had with the six DVT specialist nurses we asked questions 
seeking their expert opinion (where no data or references were available). These 
included questions like: how patients enter the system, treatment time, the percentage 
of time each type of staff is responsible, and the number of resources. According to 
their responses, typically 60% of patients first present via general practitioner 
referrals, 10% through community care, 20% outpatients and 10% A&E. The average 
staff time it takes to conduct a first and follow-up visit to the DVT clinic is 75 and 60 
minutes, respectively. On average Haematologists are responsible for 10% of all 
treatments, 80% DVT nurses and 10% radiographers. All remaining input parameters 
are entered according to the estimates provided in the appendix.  
 
The model was run for a simulation period of 5 years with a warm up period of 1 year 
(determined using the Welch method) to make sure that the results were not collected 
until all patients in the cohort had gone through the DVT care system and had an 
initial contact with a nurse, radiographer or a haematologist. The weekly simulation 
period was Monday to Friday from 9am to 5pm reflecting the current operating 
arrangements in DVT care services.  
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4.2 Model Validation 
The model validation process was carried out by comparing the expected number of 
activity results over a 5-year period using the known data in the actual care system, 
with the simulation results. As described in the previous section, the total patient 
population size is expected to reach 275 by the end of year 5. The total number of 
visits over a 5-year period was calculated taking into account the total cohort size, the 
fraction of the DVT category (i.e. provoked, unprovoked and recurrent), the number 
of visits per year for each category, and the simulation duration of 5 years. The 
difference between the real life calculations and the simulation model has been within 
the confidence interval range of 95%, giving a result from the model, which is within 
5% either side of the expected result.  This deems the model suitable to allow further 
experimentation with other scenarios. 
 
To achieve face validity, the model was shown to each nurse individually and then in 
a workshop including all six nurses. The model structure was confirmed to be highly 
representative of the real world DVT care system by all six nurses in the individual 
meetings and during the workshop where the whole group was present. In general, the 
continuous engagement of the DVT nurses throughout the study significantly 
increased confidence in the validity of the model.  
 
4.3 Experimentation 
The aim of the experiment is to assess the possible impact of shifting more DVT 
patients from hospital care to community care services using the new treatment. There 
is evidence that this should have a positive impact on the operational and financial 
performance of the DVT care system (NICE, 2014a), it is important to support this by 
stronger evidence including quantification of any benefit of such policy. In addition, 
STAR will help key decision makers better understand the interventions that are likely 
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to benefit the patients the most with the greatest savings (efficiency and productivity), 
and thus effective decision making benefiting patients, tax payers, the NHS and 
beyond.  
 
The tool enables users to input parameters for two sets of scenarios, the first for the 
baseline model (existing service) and the second for experimentation. Therefore, all 
input parameters can be customised for both scenarios. In the first scenario it is 
assumed that 100% of patients are treated in hospital (hence 0% in the community) 
and 0% on new treatment. The second scenario tests the impact of increasing 
community services for the treatment of DVT, e.g. 80% in hospital and 20% in the 
community (see Table 3 for a list of scenarios). In addition, we increase the use of 
new treatment in steps of 20% (and reduce standard of care) and investigate key 
performance metrics as in Table 3 (column 1).  
 
 
Key performance 
measure 
Baseline - 100% 
in hospital and 
0% on new 
treatment 
80% in hospital 
and 20% on new 
treatment 
60% in hospital 
and 40% on new 
treatment 
Total number of INR visits 
(first and follow-ups), 
including cancer patients 
61,494 
[57,804, 65,184] 
42,295 
[39,292, 45,298] 
34,884 
[32,930, 36,907] 
Total cost of standard of 
care (including drug costs), 
i.e., LMWH and Warfarin 
(including cancer) 
£3,039,843 
[£2,863,532, 
£3,216,154] 
£2,146,730 
[£2,015,779, 
£2,277,681] 
£1,330,469 
[£1,251,971, 
£1,408,967] 
Total cost of new treatment 
(including drug costs and 
cancer patients) 
£0.00 £201,357 
[£189,074, 
£213,841] 
£374,225 
[£352,520, 
£395,930] 
Total cost (standard of care 
+ new treatment) including 
cancer 
£3,039,843 
[£2,863,532, 
£3,216,154] 
£2,348,087 
[£2,214,246, 
£2,481,928] 
£1,704,694 
[£1,609,231, 
£1,800,157] 
Total nurse service  
hours 
11,195  
[10,523, 11,867] 
9,578 
[8,888, 10,277] 
7,125  
[6,633, 7,617]  
Total haematologist service  
hours 
4,407 [4098, 4729]  3,568 [3,372, 
3,786] 
1,549 [1,443, 
1,659] 
Table 3 Key performance metrics and the generated high level outputs from the DVT 
model (numbers in brackets is the 95% confidence interval).  
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The model was run 100 times using a different seed for each run for a period of five 
years. The results indicate that increasing use of community services (under the new 
treatment regime) will have a positive impact on the number of INR visits and its 
associated costs. The number of INR visits has reduced from 61,494 (on average) to 
42,295 under the 20% increase on new treatment (in community care). This is quite a 
significant reduction taking into account the fact that nurses in the DVT treatment 
services are highly utilised and under huge workload pressure (11,195 nurse hours 
have reduced down to 9,578). The other positive impact of the increased use of new 
treatment and its resulting decrease in the activity and nurse service hours is the cost 
savings. The total costs have reduced from £3,039,843 to £2,348,087 (£691,756 
savings). These reductions are significant in the DVT care services and the general 
health care services, where squeezed budgets and funding cuts are expected to 
become a feature of the healthcare landscape in the future (Figure 2 illustrates the 
comparison between the scenarios). Undoubtedly increased use of new treatment 
(NOAC) in the community generates huge savings, but is it value for money and more 
importantly, would patients actually benefit from this service transformation? 
According to Table 4 treating patients in the community with NOAC generates the 
highest value for money with an expected health benefit of 24,300, which is much 
greater than patients treated in the community and hospital with warfarin. Figure 3 
shows the same information as Table 4 but in graphic form.  Graphical illustration 
attracted considerable attention amongst the decision makers which had stimulated the 
discussion and generated important learning, e.g., treating patients in hospital with 
Warfarin consumed the largest amount of costing, with very little health benefit, 
whereas NOAC in the community produced a steep hypotenuse representing greater 
ratio of health benefits to costs.     
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Intervention Number 
of 
patients 
(N) 
Health 
improvement 
as indicated by 
nurses  (𝐵𝑗) 
Probability 
of success 
(𝑝𝑗) 
Expected 
Health 
Benefit 𝐸(𝑣𝑗)   
Value for 
Money 
(VfMj) 
Total Cost 
(𝑐𝑗) 
NOAC 
Community 
243 100 1 24,300 859.96 £28,257 
NOAC 
Hospital 
321 100 1 32,100 261.08 £122,953 
Warfarin 
Community 
322 30 1 9,660 38.10 £253,543.40 
Warfarin 
Hospital 
465 30 1 13,950 13.73 £1,015,999.10 
Table 4 Results based on 60% of patients been treated in hospital with Warfarin and 
40% in the community with NOAC over the 5 year simulation period (ranked by 
value for money). Probability of success (𝑝𝑗 = 1) means that the intervention 
(Warfarin or NOAC) can be successfully implemented in practice with a probability 
of 1.  
 
Note that the model is not limited to these outputs, it’s developed to generate a series 
of key performance metrics, reporting scenario 1 and scenario 2 (for each of the five 
years) with respect to arrivals; diagnosis process (wells score test, d-dimer test, 
ultrasound and repeat ultrasound); treatment process (standard of care, new treatment, 
DVT categories, cancer patients, initial treatment, follow-ups); financial reporting of 
all activities in the diagnosis and treatment phase; and staff utilisation in terms of 
service hours and full time equivalent needed to ensure services are provided 
efficiently and effectively.   
£0
£500,000
£1,000,000
£1,500,000
£2,000,000
£2,500,000
£3,000,000
£3,500,000
Baseline 20% new
treatment
40% new
treatment
Cost of Standard of
Care
Cost of New Treatment
Total Cost
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Figure 2 Costing implications of new treatment (NOAC) in community care (vs. 
standard of care in hospital, i.e., Warfarin) 
 
Figure 3 Interventions ranked according to value for money 
 
5 Discussion  
As described earlier in the paper the tool was designed with specialists in the DVT 
patient pathway.  The authors have first-hand experience of the frustration that can 
sometimes accompany planning and approving new services in healthcare systems. 
Often changes are introduced without proper consideration of the impact on the 
service. It is also often the case that those people working in the healthcare system 
know how they would like to improve the service they deliver, but lack the expertise 
to frame those improvements in a manner that will be acceptable to executives and 
holders of finance budgets. This tool therefore has been designed to allow ‘non-
experts’ to test change on the pathway in a validated simulation.  The simulation will 
present the impact of changes in a pathway in a way that can be easily understood by 
both the executive and pathway specialists. It is the authors’ intention that this will 
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facilitate service planning and decision making and speed up the pace of change in the 
DVT pathway.  Furthermore, the use of simulation as a decision making tool is still in 
its infancy in the UK. We would therefore recommend that a longer term study on the 
impact of the DVT simulation would be helpful. We would suggest following the 
progress of service development projects that use simulation, in comparison with 
those that do not. The simulation could also be improved by incorporating primary 
care data which would add considerably to the robustness of the assumptions that are 
used to support the simulation.  
 
This DVT simulation is currently being used by a major pharmaceutical company to 
facilitate service change in the UK. The simulation is being used nationwide by the 
pharmaceutical company’s healthcare development team with the objective of 
developing DVT services for the benefit of patients, the healthcare provider and the 
company, who also supply some of the drugs used in the pathway.  
 
The tool allows decision makers to better understand the operation of the system in 
relation to key performance metrics associated with activity, cost implications and 
resource utilisation. The ease of use of the tool with relevant sets of exported results 
means that senior decision makers could be more proactive with evidence based 
approach in re-designing their care pathway in finding the most efficient and effective 
delivery of care to patients with DVT.  
 
The illustrative scenarios which were tested on the simulation based DST developed 
in this research, give a clear indication of the importance of the tool to guide decision 
making in the health management sector. If we take into account the significant 
number of possible scenarios which can be simulated and the wide range of 
performance indicators incorporated in the model, the huge potential of the tool 
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becomes obvious. This can only be welcomed in the area of healthcare management 
given how important it is for the wellbeing of individuals and society, the complexity 
of the health care delivery system, and the growing challenges to improve 
effectiveness and efficiency in health care delivery. 
 
The simulation results suggest that an increased use of new treatment (or NOAC) in 
community services will have a positive impact on the workload (i.e. INR visits) and 
utilisation of DVT nurses. The policy rationale follows that making more use of new 
treatment to treat and monitor the evolution of the DVT patients health state, and 
thereby alleviate the workload pressures on nurses, is strongly supported by the 
simulation results. STAR further supports this in relation to health benefits to costs. 
The visual aids have proved essential to make the cost effectiveness analysis 
framework accessible to those key decision makers who lack quantitative ability. In 
addition, the triangles helped clinicians, nurses and commissioners to share their 
knowledge and articulate their opinions on the impact of service re-design.  
As such, the simulation based DST developed here is a very good example of the 
“evidence based decision making” tools, which have gained in popularity in the last 
few years, especially within the healthcare management sector. It is also a good 
example of how a DST can be developed and used in the context of integrating health 
(i.e. in the hospital) and social care (i.e. in the community) systems. Although the 
discrete event simulation and the STAR approach were developed for DVT patients, 
similar approach can be adapted for other disease areas. Given the uniqueness of our 
approach (i.e. combining DES with STAR within a single decision support tool), this 
paper makes a significant contribution towards empowering key decision makers to 
enable better management of patients.   
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A limitation of the study is that we did not take account of co-morbidities and 
interactions with other diseases which may impact on the speed of disease progression 
and the associated level of care. The model was built using information from a single 
context, which can “corrupt” the results and reduce confidence in the validity of the 
results and the ensuing policy decisions.  
 
The main strength of this decision support tool is the adoption of a team approach to 
studying the system, involving six DVT specialist nurses across the country, ensuring 
that a variety of views and suggestions were taken as well as systems modelling and 
simulation. This led to a model with high face validity and credibility among its users. 
Future work could explore additional ways in which the current model could 
incorporate individual patient characteristics (e.g. disease severity, age group, gender, 
etc.), which may alter patients pathway and explore the impact on activity results and 
costing. Furthermore, the evaluation of performance would be more realistic if it 
included performance indicators related to the quality of care and its impact on the 
quality of life of patients, and investigated how these aspects may affect readmission 
and mortality and the movement of patients between the different care services within 
the pathway.  
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Appendix 
  Estimate Distribution   Reference 
Demand 
Please specify prevalence rate of DVT 
within your population  
104.6  per 100,0000 
population 
Poisson Martinez et al. (2011) 
Please specify the proportion of patients 
with Cancer  
12.20% Multinomial Martinez et al. (2011) 
Please specify the % of the diagnosed  
population with RECURRENT DVT 
19% Multinomial Martinez et al. (2011) 
Please specify the annual increase for 
each year (1-5) of patient arrivals 
User specified Bernoulli N/A 
Diagnosis   
What is the percentage of DVT 
patients arriving from the following 
sources? 
      
Percentage arriving from the GP Direct User specified/Expert 
opinion 
Multinomial N/A 
Percentage arriving from Community 
Care 
User specified/Expert 
opinion 
Multinomial N/A 
Percentage arriving from outpatients User specified/Expert 
opinion 
Multinomial N/A 
Percentage arriving from Accident and 
Emergency (A&E) 
User specified/Expert 
opinion 
Multinomial N/A 
 What percentage of DVT patients 
will... 
  
 
  
have a 'Wells Score' of greater than 2 46% Bernoulli Wells et al. (2003) 
have a 'Wells Score' of less than or 
equal to 2 
54% Bernoulli Wells et al. (2003) 
What percentage of DVT patients 
will have a... 
  
 
  
positive 'D-Dimer' test result 30% Bernoulli Wells et al. (2003) 
negative 'D-Dimer' test result 70% Bernoulli Wells et al. (2003) 
What % of people will have a    
 
  
Positive first ultrasound 24% Bernoulli Goodacre et al. (2006) 
Positive repeat ultrasound 1% Bernoulli Goodacre et al. (2006) 
What percentage of DVT  patients 
will have 
  
 
  
Unprovoked 44.80% Multinomial Martinez et al. (2011) 
Provoked 36.20% Multinomial Martinez et al. (2011) 
  35 
Recurrent 19.0% Multinomial Martinez et al. (2011) 
Treatment  
What percentage of patients will 
receive the following options? 
 
  
 
Standard of Care (LMWH + Warfarin) User specified/Expert 
opinion 
Bernoulli  N/A 
 
N/A New treatment User specified/Expert 
opinion 
Bernoulli 
Please define the % of patients and 
length of treatment 
    
 
  Recurrent    
 
 
 
 
 
 
 
Bauersachs et al.  (2010) 
3 months 3% Multinomial 
6 months 42% Multinomial 
12 months 55% Multinomial 
    
 
  Provoked 
 
3 months 22% Multinomial 
6 months 63% Multinomial 
12 months 15% Multinomial 
      
  Unprovoked   
3 months 6% Multinomial 
6 months 63% Multinomial 
12 months 31% Multinomial 
Please indicate the length of 
treatment for cancer patients 
  
 
  
6 months 100% Fixed  Noble et al. (2008) 
Please indicate the number of follow 
up visits required 
Warfarin 
 
  
3 months 9 Poisson Winter et al. (2005), Rose 
et al. (2011), Keeling et al. 
(2011) 
6 months 14 Poisson 
12 months 24 Poisson 
  LMWH 
  
8 days 8 Fixed (Scottish Intercollegiate 
Guidelines Network, 
2010) 
  New treatment 
 
  
3 months 2 Poisson New treatment 
PrescribingInformation 
(PI) 
6 months 2 Poisson 
12 months 2 Poisson 
On average how much staff time does 
it take to conduct a FIRST visit to the 
DVT clinic 
User specified/Expert 
opinion 
 
Average 
N/A 
Please indicate the % of time each 
type of staff is responsible 
  
 
  
Haematologist User specified/Expert 
opinion 
Multinomial N/A 
Nurse User specified/Expert 
opinion 
Multinomial N/A 
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Radiologist User specified/Expert 
opinion 
Multinomial Expert Opinion 
On average how much staff time does 
it take to conduct a FOLLOW-UP 
visit to the DVT Clinic 
User specified/Expert 
opinion 
 
Average 
Expert Opinion 
Please indicate the percentage of time 
each type of staff is responsible 
  
 
  
 Haematologist User specified/Expert 
opinion 
Multinomial Expert Opinion 
Nurse User specified/Expert 
opinion 
Multinomial Expert Opinion 
Radiologist User specified/Expert 
opinion 
Multinomial Expert Opinion 
Costing 
Cost of FIRST Visit to 
Haematology/DVT clinic 
£247 Fixed Payment by Result (2013) 
Cost of FOLLOW-UP Visit to 
Haematology/DVT clinic 
£113 Fixed Payment by Result (2013) 
Cost of FIRST visit community DVT 
clinic 
User specified/Expert 
opinion 
Fixed  N/A 
Cost of FOLLOW-UP visit community 
DVT clinic 
User specified/Expert 
opinion 
Fixed  N/A 
New treatment price per tablet  £2.10 Fixed (MIMS) 
LMWH (NON CANCER) cost per day £9.77 Fixed (MIMS), assuming an 
average patient weight of 
80kg 
LMWH (CANCER) cost per day month 
1 
£8.47 Fixed (MIMS) assuming an 
average weight of a 
patient 69-82Kg  
LMWH (CANCER) cost per day after 
month 1 
 Fixed  
Warfarin cost per day £0.07 Fixed (MIMS) 
Salary - Hourly Cost 
 Haematologist £139 Fixed PSSRU (2013) 
Nurse £123 Fixed PSSRU (2013) 
Radiologist £139 Fixed PSSRU (2013) 
Number of resources 
 Haematologist User specified/Expert 
opinion 
Fixed N/A 
Nurse User specified/Expert 
opinion 
Fixed N/A 
Radiologist User specified/Expert 
opinion 
Fixed N/A 
Table: The input parameters associated with the DVT model. 
 
